Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of intravitreal bevacizumab
2013-005056-15Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in Subretinal neovascularization, macular edema and neovascular retinopathy (NVR), sponsored by Ghent University Hospital. Primary endpoint: Comparison of center outcomes with phase 3 trial results. Started Feb 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
Subretinal neovascularizationmacular edemaneovascular retinopathy (NVR)
Beyond the preview
Go deeper on 2013-005056-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005056-15.